Genelux (NASDAQ:GNLX) Raised to “Hold” at Wall Street Zen

Genelux (NASDAQ:GNLX) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

GNLX has been the topic of several other reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Genelux in a research report on Wednesday, October 8th. Loop Capital set a $16.00 price target on shares of Genelux in a research note on Tuesday, October 21st. Maxim Group set a $20.00 price target on Genelux in a report on Tuesday, October 21st. Finally, Lake Street Capital initiated coverage on Genelux in a report on Tuesday, October 21st. They issued a “buy” rating and a $16.00 price objective for the company. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $21.00.

Genelux Price Performance

NASDAQ:GNLX opened at $4.55 on Friday. The firm has a market capitalization of $173.13 million, a P/E ratio of -5.17 and a beta of 0.17. The business has a 50 day simple moving average of $5.29 and a 200 day simple moving average of $4.38. Genelux has a 12-month low of $1.99 and a 12-month high of $8.53.

Genelux (NASDAQ:GNLX) last issued its earnings results on Wednesday, November 5th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.02. Research analysts anticipate that Genelux will post -0.88 EPS for the current fiscal year.

Insider Activity

In related news, Director John Thomas sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $5.00, for a total transaction of $50,000.00. Following the transaction, the director owned 492,784 shares in the company, valued at $2,463,920. This trade represents a 1.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 15,990 shares of company stock valued at $82,054 in the last ninety days. Company insiders own 8.80% of the company’s stock.

Hedge Funds Weigh In On Genelux

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GNLX. Creative Planning raised its stake in shares of Genelux by 4.7% in the 3rd quarter. Creative Planning now owns 46,108 shares of the company’s stock worth $194,000 after buying an additional 2,084 shares in the last quarter. Raymond James Financial Inc. grew its holdings in Genelux by 22.6% during the second quarter. Raymond James Financial Inc. now owns 28,933 shares of the company’s stock worth $83,000 after acquiring an additional 5,333 shares during the period. Geode Capital Management LLC grew its holdings in Genelux by 1.8% during the second quarter. Geode Capital Management LLC now owns 318,825 shares of the company’s stock worth $915,000 after acquiring an additional 5,596 shares during the period. 5T Wealth LLC raised its position in Genelux by 33.9% in the third quarter. 5T Wealth LLC now owns 24,101 shares of the company’s stock worth $101,000 after acquiring an additional 6,100 shares in the last quarter. Finally, LifeSteps Financial Inc. lifted its holdings in Genelux by 8.2% in the 3rd quarter. LifeSteps Financial Inc. now owns 105,171 shares of the company’s stock valued at $442,000 after acquiring an additional 7,952 shares during the last quarter. 37.33% of the stock is owned by institutional investors.

Genelux Company Profile

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.